(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 11.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Codexis's revenue in 2026 is $77,679,000.On average, 9 Wall Street analysts forecast CDXS's revenue for 2026 to be $8,276,555,224, with the lowest CDXS revenue forecast at $7,726,726,778, and the highest CDXS revenue forecast at $8,715,563,836. On average, 8 Wall Street analysts forecast CDXS's revenue for 2027 to be $9,933,377,449, with the lowest CDXS revenue forecast at $8,692,567,626, and the highest CDXS revenue forecast at $12,521,984,228.
In 2028, CDXS is forecast to generate $11,797,056,063 in revenue, with the lowest revenue forecast at $9,905,234,467 and the highest revenue forecast at $13,676,174,991.